Introduction
Type 2 diabetes, until recently considered a permanent and inevitably progressive chronic disease, impacts rates of mortality and morbidity as well as quality of life (QoL). Affecting between 5% and 35% of post-industrial adult populations [
1], it presents a major and increasing economic burden, currently accounting for 10% of total healthcare expenditure in the UK [
2] and 12.5% in the USA [
3]. Management has usually focused on pharmacotherapy, with increasing emphasis in guidelines on earlier prescription of more modern and expensive glucose-lowering, lipid-lowering and antihypertensive drugs, to control blood glucose and reduce the associated complications and elevated cardiovascular risks. Despite these treatments, younger people, in particular, commonly face irreversible declines in health from type 2 diabetes, characterised by chronic pain and multiple disabilities, and life expectancy is reduced substantially [
4]. However, remission of type 2 diabetes is now known to be possible [
5‐
7]. In the Diabetes Remission Clinical Trial (DiRECT), an integrated diet programme delivered entirely within primary care produced remissions of type 2 diabetes (non-diabetic HbA
1c on no glucose-lowering medication) in 46% of participants at 1 year and 36% at 2 years [
8,
9].
The DiRECT study, reported in detail elsewhere [
8,
10], recruited 298 adults with a diagnosis of diabetes within the past 6 years, BMI 27–45 kg/m
2 and HbA
1c >48 mmol/mol (6.5%), or >42 mmol/mol (6.0%) if receiving glucose-lowering medication. Half the participants were in practices randomised to receive the Counterweight-Plus weight management programme, and all received usual care under current clinical guidelines. The Counterweight-Plus programme is initiated as ‘total diet replacement’ with a low-energy formula diet (soups and shakes) providing 3452–3569 kJ (825–853 kcal) per day for 12–20 weeks (Counterweight, UK). This is followed by structured food reintroduction for 2–8 weeks and a subsequent longer-term programme of weight loss maintenance. For relapse management, 2–4 week ‘rescue packages’ of the formula diet are provided if >2 kg weight is regained or if diabetes returns. All oral glucose-lowering and antihypertensive medications are suspended on safety grounds at the start of the programme but are reintroduced according to blood glucose and blood pressure measurements taken at each primary care appointment, following clinical guidelines.
Remission of type 2 diabetes has the potential to lead to substantial long-term health gains and cost savings. Decision analytic models are commonly used to extrapolate long-term costs and outcomes from clinical trials, supplementing trial data with other sources of evidence on longer-term disease progression such as diabetes relapse, health-related QoL, mortality and costs [
11]. Here we report a lifetime cost-effectiveness analysis of the Counterweight-Plus intervention, based on resource use measured in DiRECT over 2 years, and projected longer-term cost and quality-adjusted life-years (QALYs), assuming a limited duration of diabetes remission.
Methods
A within-trial cost analysis was conducted using the 2 year data from DiRECT, including both the intervention costs and routine healthcare resource use measured during the time course of the study, for all participants (including those who did not complete the trial or who were unsuccessful in achieving remission). Lifetime cost-effectiveness was then estimated by predicting time to relapse (i.e. re-emergence of diabetes, assumed to be permanent thereafter) among those who were in remission at 2 years, applying the mean management costs for type 2 diabetes incurred within the UK National Health Service (NHS), under clinical guidelines which tend to favour older, less expensive medications. An NHS perspective for costing was adopted for both within-trial and lifetime analyses. Costs are presented in 2018 UK prices (£).
Discussion
It is most unusual to be able to provide a new medical treatment for a major chronic disease which is both health-improving and cost-saving. The DiRECT study has shown that durable remissions of type 2 diabetes to a non-diabetic state can be achieved through an integrated weight management programme, mostly for those achieving weight loss >10 kg, for almost half of all participants. Weight loss >15 kg in the intervention arm led to remissions for 86% at 1 year and 82% at 2 years [
9]. The present analysis indicates that the intervention is likely to generate QALY gains and be not only cost-effective but also cost-saving after 5–6 years. Given the rate at which second-line glucose-lowering medication costs have been rising in recent years, cost-saving estimates may be conservative.
Although individuals with remissions are assumed to relapse to diabetes over time, cost savings were modelled to accrue beyond the point of relapse, with a delay in the requirement for more intense resource use due to diabetic complications. We have previously noted that roll-out of the intervention in routine practice may provide for efficiencies that could reduce costs; however, even under trial conditions, set-up costs are a minor component of total intervention costs, and no adjustment was made for such efficiencies in the present analysis.
There were fewer medical appointments for intercurrent medical problems in the DiRECT intervention group and fewer serious adverse events in year 2 [
9]. This is in line with improved diabetes control and remissions for many. Better QoL would therefore be expected, and this was borne out by a general pattern of modestly improved EuroQol EQ-5D scores in the intervention group at both 12 and 24 months. [
9] However, the mean duration of diabetes at baseline, of 3 years, is too short for the full impact of diabetes and its complications to have already impaired QoL. Therefore, QoL measurements over a 2 year period so early in the disease course cannot be expected to capture the long-term impact of more sustained diabetes remissions. Given that diabetes ultimately carries a major long-term burden for health-related QoL, we calculated QALY losses using a health state utility decrement due to diabetes based on the US Medical Expenditure Panel Survey [
20]. Long-term health gains in our analysis are, however, attributable principally to improved life expectancy due to periods of remission, as our model assumed, perhaps conservatively, that over time all individuals in remission would return to the diabetes state by 10 years.
In the analysis of the Scottish Care Information Diabetes Database (SCI-Diabetes), life expectancy was found to be significantly lower in people with type 2 diabetes, irrespective of age group or socioeconomic status (with the exception of men >80 years in the most deprived quintile) [
18]. These published Scottish survival rate data, on which estimates of life expectancy losses were based, are somewhat more conservative than the estimates from a large European study [
22], which indicated that the years of life lost for people without known vascular disease would be about 5.2 years for men and 6.1 years for women.
An important assumption in our analysis was that remission returned participants to a life expectancy similar to that of the diabetes-free population. However, the benefit in terms of reduced mortality risk was modelled to be temporary, as all individuals in remission were assumed to relapse to diabetes within 10 years, and many were assumed to do so within 5 years. As yet, there are no published data from any country on the future health or life expectancy of people who achieve dietary--weight-loss-induced remissions of type 2 diabetes. Many of the participants in remission from diabetes in DiRECT had HbA
1c in the range of ‘prediabetes’ (42–48 mmol/mol [6.0–6.5%]). About 30–40% of the adult population have HbA
1c in this range, which is associated with progression to type 2 diabetes for perhaps a fifth, and poorer health outcomes than with lower HbA
1c [
23‐
25]. The health outcomes for people in this range, which may be considered ‘post-diabetes’, after improving diet and lifestyle, are still unknown: they may be worse or better than those of the general population.
No subgroup effects have been proposed clinically, and we did not seek to do so. Relapse to diabetes in year 2, however, was significantly more likely among women than among men (
p= 0.016). The SCI-Diabetes analysis found that women with diabetes lost more years of life compared with men [
18]. A very large European study found a similar difference between sexes [
22]. When we performed separate analyses for men and women, however, we modelled greater life expectancy gains in men than in women because of the lower rates of relapse in men, though life-year and QALY gains remained statistically significant for both; the intervention was cost-saving in both men and women, and the noted difference in relapse could be due to chance. These results should not imply withholding treatment for women, as they still did very well, but there may be benefit from modifying the intervention in the future to better support maintenance of weight loss and diabetes remission in women.
The present analysis is based on UK data both in terms of the DiRECT trial itself, and other data for costs of diabetes care under the NHS, and observed long-term mortality. Intervention costs in other countries may differ; though, as noted above, more efficient delivery, both in the UK and elsewhere, might be expected once the programme is established in routine practice. The major element of intervention cost is the formula diet, whose acquisition cost might fall in the future through economies of scale. Costs of routine diabetes care under clinical guidelines may be expected to increase with wider and earlier use of newer medications and an increasing duration of disease after younger onset.
A 2019 position statement issued by the joint Association of British Clinical Diabetologists and the Primary Care Diabetes Society [
5] reviewed the current evidence for remission of type 2 diabetes, ranging from bariatric surgery, in 1987 [
26], to the most recent evidence of dietary and behavioural interventions including DiRECT [
9,
27,
28]. It concluded there was ample evidence to support the recommendation of achieving remission through weight loss, but that long-term follow-up was needed given the risk of weight regain. Relapse into diabetes, driven by weight regain, incurs costs from relapse management and from resumption of progressive costs for diabetes and its complications. Though relapse had a bearing on outcomes in our study, even relatively rapid relapse did not alter the conclusion that the low-energy diet intervention was capable of producing long-term health gains without adding long-term costs. The Counterweight-Plus intervention may therefore be expected to be transferable to other diabetes care settings in a similarly cost-effective manner.
Acknowledgements
We thank the NHS Primary Care Research Network and North East Commissioning Support for their support and valuable input to the study recruitment. We thank M. McNee, E. Butler, J. Cooney, S.-J. Duffus and P. Stewart, from the University of Glasgow (Glasgow, UK), for providing technical assistance; H. Pilkington, from the Newcastle upon Tyne Hospitals NHS Foundation Trust (Newcastle upon Tyne, UK), for providing research nurse support; and S. Weeden and S. Boyle, from the Robertson Centre for Biostatistics (University of Glasgow, Glasgow, UK), for project and data management. We are grateful to the general practices, healthcare professionals and volunteers who participated in this study.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.